LMFLOSS: A Hybrid Loss For Imbalanced Medical Image Classification
Authors:
Abu Adnan Sadi,
Labib Chowdhury,
Nursrat Jahan,
Mohammad Newaz Sharif Rafi,
Radeya Chowdhury,
Faisal Ahamed Khan,
Nabeel Mohammed
Abstract:
Automatic medical image classification is a very important field where the use of AI has the potential to have a real social impact. However, there are still many challenges that act as obstacles to making practically effective solutions. One of those is the fact that most of the medical imaging datasets have a class imbalance problem. This leads to the fact that existing AI techniques, particular…
▽ More
Automatic medical image classification is a very important field where the use of AI has the potential to have a real social impact. However, there are still many challenges that act as obstacles to making practically effective solutions. One of those is the fact that most of the medical imaging datasets have a class imbalance problem. This leads to the fact that existing AI techniques, particularly neural network-based deep-learning methodologies, often perform poorly in such scenarios. Thus this makes this area an interesting and active research focus for researchers. In this study, we propose a novel loss function to train neural network models to mitigate this critical issue in this important field. Through rigorous experiments on three independently collected datasets of three different medical imaging domains, we empirically show that our proposed loss function consistently performs well with an improvement between 2%-10% macro f1 when compared to the baseline models. We hope that our work will precipitate new research toward a more generalized approach to medical image classification.
△ Less
Submitted 24 December, 2022;
originally announced December 2022.
IMPECCABLE: Integrated Modeling PipelinE for COVID Cure by Assessing Better LEads
Authors:
Aymen Al Saadi,
Dario Alfe,
Yadu Babuji,
Agastya Bhati,
Ben Blaiszik,
Thomas Brettin,
Kyle Chard,
Ryan Chard,
Peter Coveney,
Anda Trifan,
Alex Brace,
Austin Clyde,
Ian Foster,
Tom Gibbs,
Shantenu Jha,
Kristopher Keipert,
Thorsten Kurth,
Dieter Kranzlmüller,
Hyungro Lee,
Zhuozhao Li,
Heng Ma,
Andre Merzky,
Gerald Mathias,
Alexander Partin,
Junqi Yin
, et al. (11 additional authors not shown)
Abstract:
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silicomethodologies need to be improved to better select lead compounds that can proceed to later stages of the drug discovery protocol accelerating…
▽ More
The drug discovery process currently employed in the pharmaceutical industry typically requires about 10 years and $2-3 billion to deliver one new drug. This is both too expensive and too slow, especially in emergencies like the COVID-19 pandemic. In silicomethodologies need to be improved to better select lead compounds that can proceed to later stages of the drug discovery protocol accelerating the entire process. No single methodological approach can achieve the necessary accuracy with required efficiency. Here we describe multiple algorithmic innovations to overcome this fundamental limitation, development and deployment of computational infrastructure at scale integrates multiple artificial intelligence and simulation-based approaches. Three measures of performance are:(i) throughput, the number of ligands per unit time; (ii) scientific performance, the number of effective ligands sampled per unit time and (iii) peak performance, in flop/s. The capabilities outlined here have been used in production for several months as the workhorse of the computational infrastructure to support the capabilities of the US-DOE National Virtual Biotechnology Laboratory in combination with resources from the EU Centre of Excellence in Computational Biomedicine.
△ Less
Submitted 13 October, 2020;
originally announced October 2020.
